Kite Pharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$169.2M
Doctors Paid
6,373
Transactions
34,146
2024 Total
$21.3M
Payment Breakdown by Category
Research$157.2M (92.9%)
Consulting$4.4M (2.6%)
Travel$1.1M (0.7%)
Food & Beverage$687,338 (0.4%)
Royalty/License$200,000 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $157.2M | 8,267 | 92.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.7M | 1,426 | 2.8% |
| Consulting Fee | $4.4M | 1,503 | 2.6% |
| Travel and Lodging | $1.1M | 2,885 | 0.7% |
| Food and Beverage | $687,338 | 19,808 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $428,990 | 120 | 0.3% |
| Grant | $428,900 | 13 | 0.3% |
| Royalty or License | $200,000 | 1 | 0.1% |
| Education | $3,573 | 123 | 0.0% |
Payments by Type
Research
$157.2M
8,267 transactions
General
$12.0M
25,879 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) | $18.7M | 0 | 1,780 |
| Cooperative Research and Development Agreement for the Development of NCI Proprietary Peripheral Blood Autologous T Cell Therapies Using Retrovirally Modified Peripheral Blood Lymphocytes that Express NCI Proprietary T-cell Receptors, Newly Discovered Receptors, and/or NCI Proprietary Chimeric Antigen Receptors for Use in Immunotherapy for Patients with Metastatic Cancer, Utilizing the Expertise of Kite Pharma in the Development and Manufacturing of Cancer Immunotherapies. | $17.5M | 0 | 14 |
| A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | $16.0M | 0 | 905 |
| A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | $12.5M | 23 | 1,004 |
| Cooperative Research and Development Agreement for the Development of T-cell Therapy Using Neoantigen Reactive T Cell Receptors Retrovirally Transduced into Autologous Peripheral Blood Lymphocytes | $10.4M | 0 | 14 |
| A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA 6) | $5.8M | 0 | 210 |
| A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | $4.1M | 0 | 331 |
| A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Rituximab or Lenalidomide in Subjects with Refractory Large B-Cell Lymphoma (ZUMA-14) | $3.7M | 0 | 375 |
| A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | $3.5M | 0 | 396 |
| A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects with Relapsed/Refractory Large B-cell Lymphoma (ZUMA 9) | $3.4M | 0 | 333 |
| A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA 3) | $3.4M | 0 | 328 |
| A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) | $3.3M | 0 | 484 |
| Clinical Development of T Cell Receptor Gene Therapy Targeting HPV-16 E6 and E6 for HPV-Associated Cancers | $2.7M | 0 | 2 |
| A Multicenter, Open-label Expanded Access Study of KTE-X19 in Subjects with B-Cell Malignancies | $2.6M | 0 | 272 |
| A Phase 1 Study Evaluating the Safety and Efficacy of MAGE - A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers | $2.6M | 0 | 242 |
| Predictive Markers and Evolutionary Dynamics of Axicabatagene Ciloleucel in NHL Patients | $2.5M | 0 | 5 |
| PA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (Phase 1 Cohort 1&2) (Phase 2 Cohort 3&4 ZUMA 1 - Safety Management Study) | $2.1M | 0 | 379 |
| SOC Biomarker: A holistic approach to identification of tumor features and product characteristics that contribute to response to axi-cel therapy in DLBCL and augmentation of activity | $2.0M | 0 | 1 |
| Clinical Evaluation of NCI-hCD19-CAR, a CD19-Targeting Chimeric Antigen Receptor (CAR) for the Treatment of B Cell Lymphoma and B cell Leukemia, and the Development of Novel CARs Targeting B Cell Malignancies | $2.0M | 0 | 3 |
| Kite Master Collaboration Agreement | $1.8M | 0 | 1 |
| Clinical Evaluation of NCI-hCD19-CAR, a CD19-Targeting Chimeric Antigen Receptor (CAR), Evaluation of 5F11-28Z, a CD30-Targeting CAR, Evaluation of Hu1928-2.1.2BB CAR (also known as Hu1928-Hu20BB), a Bicistronic CAR targeting CD19 and CD20, and the Development of Novel CARs Targeting B-Cell Malignancies | $1.7M | 0 | 3 |
| A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA 4) | $1.5M | 0 | 130 |
| Phase 1 Trial of GPC-2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma | $1.4M | 0 | 12 |
| Real world, DFCI - Multi parameter analysis of tissue biopsies, PBMC/products | $1.4M | 0 | 2 |
| Genetic variants associated with toxicity in DLBCL | $1.4M | 0 | 10 |
| A Phase 1-2 Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with 4-1BB DLBCL | $1.4M | 0 | 160 |
| GPC2 - Directed Chimeric Antigen Receptor Autologous T-Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma | $1.3M | 0 | 11 |
| ISR: WAVE-7 (Oluwole), Safety and Feasibility Study of Chimeric Antigen Receptor (CAR) T Cell Therapy with YESCARTA in the Outpatient Setting | $1.3M | 0 | 7 |
| Collaborative: WAVE 1, A Phase I study of anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory primary and secondary central nervous system (CNS) lymphoma | $1.2M | 0 | 9 |
| Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel | $1.2M | 0 | 124 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Ahmed Galal, Md, MD | Hematology | Cincinnati, OH | $471,329 | $0 |
| Ran Reshef, Md, MD | Hematology & Oncology | New York, NY | $431,389 | $0 |
| Dr. Javier Munoz, M.d., M.s., F.a.c.p, M.D., M.S., F.A.C.P | Internal Medicine | Phoenix, AZ | $262,996 | $0 |
| Mehrad Abedi, M.d, M.D | Specialist | Sacramento, CA | $224,247 | $0 |
| Usama Gergis, Md, MD | Hematology & Oncology | Allentown, PA | $157,055 | $0 |
| John Pagel, Md Phd, MD PHD | Hematology & Oncology | Seattle, WA | $156,437 | $0 |
| Dr. Mitchell Cairo, Md, MD | Pediatric Hematology-Oncology | Hawthorne, NY | $156,188 | $0 |
| Dr. Lori Leslie, M.d, M.D | Hematology | Hackensack, NJ | $155,520 | $0 |
| Dr. Peter Mcsweeney, Md, MD | Hematology & Oncology | Denver, CO | $143,516 | $0 |
| Salman Fazal, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $139,785 | $0 |
| Dr. Matthew Mckinney, M.d, M.D | Hematology & Oncology | Durham, NC | $138,885 | $0 |
| Peter Riedell | Hematology & Oncology | Chicago, IL | $137,201 | $0 |
| Dr. Houston Holmes, M.d, M.D | Hematology & Oncology | Dallas, TX | $132,520 | $0 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $123,072 | $0 |
| Dr. Christopher Maisel, Md, MD | Hematology & Oncology | Dallas, TX | $120,730 | $0 |
| Bradley Hunter, Md, Mph, MD, MPH | Medical Oncology | Salt Lake City, UT | $118,560 | $0 |
| Dr. Alan Zausner Skarbnik, Md, MD | Hematology & Oncology | Charlotte, NC | $116,612 | $0 |
| Dr. Matthew Lunning, D.o, D.O | Internal Medicine | Omaha, NE | $111,329 | $0 |
| Nilanjan Ghosh, Md, MD | Medical Oncology | Charlotte, NC | $110,864 | $0 |
| Anand Tandra, M.d, M.D | Hematology & Oncology | Indianapolis, IN | $109,964 | $0 |
| Dr. David Rizzieri, M.d, M.D | Medical Oncology | Charlotte, NC | $109,368 | $0 |
| Cyrus Khan, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $99,902 | $0 |
| Marco Davila, M.d, M.D | Medical Oncology | Buffalo, NY | $93,270 | $0 |
| Yi Lin, M.d, M.D | Hematology & Oncology | Rochester, MN | $90,925 | $0 |
| Joseph Mcguirk, D.o, D.O | Hematology & Oncology | Kansas City, KS | $90,154 | $0 |
About Kite Pharma, Inc.
Kite Pharma, Inc. has made $169.2M in payments to 6,373 healthcare providers, recorded across 34,146 transactions in the CMS Open Payments database. In 2024, the company paid $21.3M. The top product by payment volume is Yescarta ($65.6M).
Payments were distributed across 113 medical specialties. The top specialty by payment amount is Hematology & Oncology ($5.4M to 2,216 doctors).
Payment categories include: Food & Beverage ($687,338), Consulting ($4.4M), Research ($157.2M), Travel & Lodging ($1.1M), Royalties ($200,000).
Kite Pharma, Inc. is associated with 2 products in the CMS Open Payments database.